← Oncology Approval Tracker

FDA DECISION ·

Etcamah + CDK4/6 inhibitor

camizestrant with abemaciclib, palbociclib or ribociclib · AstraZeneca

Accelerated approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer when an FDA-authorized test detects an ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy.

SUPPORTING DATA

Evidence behind the decision

Study
SERENA-6 randomized 315 patients with ESR1 mutations detected on therapy to switch to camizestrant or continue the aromatase inhibitor, with CDK4/6 inhibition in both groups.
Key result
Median progression-free survival was 16.0 vs 9.2 months (hazard ratio 0.44, 95% CI, 0.31–0.60).
Safety to report
The label has a boxed warning for arrhythmia risk with concomitant QTc-prolonging drugs and includes a bradycardia warning.
Evidence limits
Overall survival was immature at the progression-free survival analysis. Continued approval may depend on confirmatory evidence.

LAMPGEN ANALYSIS

Why it matters

This makes an emerging ESR1 mutation actionable during ongoing treatment. SERENA-6 tested a switch before clinical progression, and overall survival was immature at the progression-free survival analysis.

What research teams should watch

Serial ctDNA collection, result turnaround and the clinical handoff determine whether a mutation-triggered switch can happen as intended. Medication reconciliation and cardiac safety checks also matter.

PRIMARY RECORDS

Sources